stockrowOrganon & Co.
OGNHealthcare Drug Manufacturers General
Organon & Co.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, down 2.92% from fiscal 2024.
- Revenue
- −1.75%
- EPS
- +1.64%
- Free cash flow
- +118.8%
- Total debt
- −3.10%
Quarter to September 2026, against a year earlier
Follow OGN
Alert me
Organon & Co. (OGN) Free cash flow
Organon & Co.'s free cash flow for fiscal 2025 was $415.0M, down 37.4% from $663.0M in fiscal 2024. Over the twelve months to 30 September 2026 it was $572.0M. Over the past ten years it has ranged from $415.0M (fiscal 2025) to $3.6B (fiscal 2018) — the current reading is the lowest in ten years. Organon & Co. ranks 16th of 21 Drug Manufacturers General companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $415.0M | (37.41%) |
| FY2024 | $663.0M | 21.21% |
| FY2023 | $547.0M | 0.37% |
| FY2022 | $545.0M | (69.43%) |
| FY2021 | $1.8B | (12.34%) |
| FY2020 | $2.0B | (30.63%) |
| FY2019 | $2.9B | (18.96%) |
| FY2018 | $3.6B | 5.82% |
| FY2017 | $3.4B | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | $326.0M | 951.61% |
| Jun 2026 | $31.0M | (83.51%) |
| Mar 2026 | $188.0M | 95.83% |
| Dec 2025 | $96.0M | (35.57%) |
| 25 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| SNY Sanofi compare | $23.8B |
| PFE Pfizer Inc. compare | $11.8B |
| BMY Bristol Myers Squibb Company compare | $9.3B |
| GSK GSK PLC Sponsored ADR compare | $8.8B |
| NVO Novo Nordisk A/S compare | $6.9B |
| BIIB Biogen Inc. compare | $1.7B |
| GRFS Grifols, S.A. compare | $750.4M |
| OGN Organon & Co. | $572.0M |
| AMRN Amarin Corporation PLC compare | $37.5M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on OGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement